enoxacin has been researched along with Osteoporosis in 2 studies
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most agents for treating osteoporosis focus primarily on anti-resorption by inhibiting osteoclast activity." | 5.62 | Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment. ( Dai, M; Lai, Q; Li, X; Liu, X; Liu, Y; Mo, F; Xu, H; Xu, Q; Zhan, P; Zhang, B, 2021) |
| "Postmenopausal osteoporosis is a common systemic skeletal disease that is associated with estrogen‑deficiency." | 5.48 | Bis‑enoxacin blocks alveolar bone resorption in rats with ovariectomy‑induced osteoporosis. ( Liu, X; Lu, E; Mao, C; Qin, A; Xu, X; Zhang, X, 2018) |
| "Most agents for treating osteoporosis focus primarily on anti-resorption by inhibiting osteoclast activity." | 1.62 | Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment. ( Dai, M; Lai, Q; Li, X; Liu, X; Liu, Y; Mo, F; Xu, H; Xu, Q; Zhan, P; Zhang, B, 2021) |
| "Postmenopausal osteoporosis is a common systemic skeletal disease that is associated with estrogen‑deficiency." | 1.48 | Bis‑enoxacin blocks alveolar bone resorption in rats with ovariectomy‑induced osteoporosis. ( Liu, X; Lu, E; Mao, C; Qin, A; Xu, X; Zhang, X, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, Q | 1 |
| Zhan, P | 1 |
| Li, X | 1 |
| Mo, F | 1 |
| Xu, H | 1 |
| Liu, Y | 1 |
| Lai, Q | 1 |
| Zhang, B | 1 |
| Dai, M | 1 |
| Liu, X | 2 |
| Zhang, X | 1 |
| Xu, X | 1 |
| Mao, C | 1 |
| Qin, A | 1 |
| Lu, E | 1 |
2 other studies available for enoxacin and Osteoporosis
| Article | Year |
|---|---|
Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment.
Topics: Actins; Animals; Biomarkers; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal | 2021 |
Bis‑enoxacin blocks alveolar bone resorption in rats with ovariectomy‑induced osteoporosis.
Topics: Alveolar Bone Loss; Animals; Body Weight; Bone and Bones; Bone Density Conservation Agents; Diphosph | 2018 |